Volume 3 Number 7
 July 2015

Home > Publications > Recurrent Prostate Cancer > Volume 3 - Year 2015 > Number 7, July 2015

Contents


Case reports






Detection, diagnosis and evaluation

Etchebehere E, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM.
Prognostic factors in patients treated with radium-223: the role of skeletal tumor burden on baseline 18F-fluoride-PET/CT in predicting overall survival.
J Nucl Med. 2015 Jun 11. pii: jnumed.115.158626. [Epub ahead of print]
Abstract | Similar articles

Lopes Dias J, Lucas R, Magalhăes Pina J, Joăo R, Costa NV, Leal C, Bilhim T, Campos Pinheiro L, Mateus Marques R.
Post-treated prostate cancer: normal findings and signs of local relapse on multiparametric magnetic resonance imaging.
Abdom Imaging. 2015 Jun 24. [Epub ahead of print]
Abstract | Similar articles

Masselli G, Monti R, Guida M, Gualdi G.
Giant Schmorl's Node may Cause High Uptake and Mimic a Bone Metastasis on (18)F-Choline Positron Emission Tomography/Computed Tomography.
World J Nucl Med. 2015 May-Aug;14(2):140-1. doi: 10.4103/1450-1147.154233.
Abstract | Full text | Similar articles

Morigi JJ, Stricker P, Van Leeuwen P, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.
Prospective Comparison of the detection rate of18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy.
J Nucl Med. 2015 Jun 25. pii: jnumed.115.160382. [Epub ahead of print]
Abstract | Similar articles

Shah VA, Rixey A, Dusing RW.
Prostate Cancer Metastases To Inguinal Lymph Nodes Detected By 11C-Acetate PET/CTAC.
J Nucl Med Technol. 2015 Jun 25. pii: jnmt.115.157594. [Epub ahead of print]
Abstract | Similar articles






Biomarkers
Davis JW.
Use of genomic markers to risk stratify men with prostate cancer.

Trends In Urology & Mens Health
, May/June 2015
Abstract | Full text

Decipher genomic classifier
Clinical practice decisions
Allen Edel
Genomic classifier can help identify patients who may not need adjuvant radiation
Prostate Cancer InfoLink, Posted on
Abstract | Full text

Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J.
Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery.
BJU Int. 2015 Mar;115(3):419-29. doi: 10.1111/bju.12789. Epub 2014 Aug 11.
Abstract | Full text | Similar articles

Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J.
Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group.
Oncotarget. 2013 Apr;4(4):600-9.
Abstract | Full text | Similar articles

Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ.
Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Eur Urol. 2015 Feb;67(2):326-33. doi: 10.1016/j.eururo.2014.05.039. Epub 2014 Jul 2.
Abstract | Full text | Similar articles

Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ.
Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.
J Clin Oncol. 2015 Mar 10;33(8):944-51. doi: 10.1200/JCO.2014.59.0026. Epub 2015 Feb 9. Erratum in: J Clin Oncol. 2015 Apr 20;33(12):1416.
Abstract | Similar articles

Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E.
A genomic classifier to improve prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
2015 Genitourinary Cancers Symposium, J Clin Oncol 33, 2015 (suppl 7; abstr 154); 2015 Feb.
Abstract

Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E.
A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Eur Urol. 2015 Apr;67(4):778-86. doi: 10.1016/j.eururo.2014.10.036. Epub 2014 Nov 12.
Abstract | Similar articles

Lobo JM, Dicker AP, Buerki C, Daviconi E, Karnes RJ, Jenkins RB, Patel N, Den RB, Showalter TN.
Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.
PLoS One. 2015 Apr 2;10(3):e0116866. doi: 10.1371/journal.pone.0116866. eCollection 2015.
Abstract | Full text | Similar articles

Ross AE, D'Amico AV, Freedland SJ.
Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer.
Prostate Cancer Prostatic Dis. 2015 Jun 30. doi: 10.1038/pcan.2015.31. [Epub ahead of print]
Abstract | Similar articles

Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, Han M, Partin AW, Trock BJ, Schaeffer EM.
Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Eur Urol. 2015 Jun 6. pii: S0302-2838(15)00444-3. doi: 10.1016/j.eururo.2015.05.042. [Epub ahead of print]
Abstract | Similar articles

Ross A, Michael Hiroshi Johnson, Kasra Yousefi, Elai Davicioni, Helen L. Fedor, Stephanie Glavaris, Voleak Choeurng, Christine Buerki, Lucia L.C. Lam, Nicholas Erho, Elizabeth B. Humphreys, George J. Netto, Misop Han, Alan W. Partin, Bruce J. Trock and Edward M. Schaeffer
Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort.
2015 ASCO Annual Meeting (May 29 - June 2, 2015). J Clin Oncol, Vol 33, No 15_suppl (May 20 Supplement), 2015: 5059
Abstract

Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, Schaeffer EM.
A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.
Prostate Cancer Prostatic Dis. 2014 Mar. doi: 10.1038/pcan.2013.49. Epub 2013 Oct 22.
Abstract | Full text | Related citations

Sedelaar JP, Schalken JA
The need for a personalized approach for prostate cancer management.
BMC Med. 2015 May 9;13:109. doi: 10.1186/s12916-015-0344-1.
Abstract | Full text | Similar articles

Discovery and validation
Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB.
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy.
PLoS One. 2013 Jun 24;8(6):e66855. doi: 10.1371/journal.pone.0066855. Print 2013.
Abstract | Full text | Similar articles

Feng FY, Ghadessi M, Davicioni E, Crisan A, Erho N, Mitra AP, Triche TJ, Jenkins RB, Ross AE, Schaeffer EM.
Validation of a Genomic Classifier That Predicts Metastatic Disease Progression in Men With Biochemical Recurrence Post-Radical Prostatectomy

Int J Radiat Oncol Biol Phys, Oct 1, Vol. 87, Issue 2, Supplement, Page S125
Abstract

Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, Triche TJ, Kollmeyer T, Ballman KV, Black PC, Klee GG, Jenkins RB.
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population.
J Urol. 2013 Dec;190(6):2047-53. doi: 10.1016/j.juro.2013.06.017. Epub 2013 Jun 11.
Abstract | Full text | Similar articles

Ross A, Kasra Yousefi, Bruce J. Trock, Voleak Choeurng, Lucia L.C. Lam, Helen L. Fedor, Mercedeh Ghadessi, Christine Buerki, Stephanie Glavaris, Debasish Sundi, Jeffrey Tosoian, Misop Han, Elizabeth B. Humphreys, Alan W. Partin, George J. Netto, Elai Davicioni, Edward M. Schaeffer
Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise.
2015 Genitourinary Cancers Symposium, J Clin Oncol 33, 2015 (suppl 7; abstr 173); 2015 Feb.
Abstract

Ross AE, Mercedeh Ghadessi, Elai Davicioni, Anamaria Crisan, Christine Buerki, Nicholas Erho, Anirban Pradip Mitra, Darby J. S. Thompson, Timothy J. Triche, Edward M Schaeffer, Felix Yi-Chung Feng
Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy.
2013 Genitourinary Cancers Symposium, J Clin Oncol 31, 2013 (suppl 6; abstr 52)
Abstract

Molecular subtyping
Mills IG.
Molecular Subtyping of Prostate Cancer: A Partnership Model.
Eur Urol. 2015 May 19. pii: S0302-2838(15)00414-5. doi: 10.1016/j.eururo.2015.05.012. [Epub ahead of print]
Abstract | Similar articles

Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.
Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes.
Eur Urol. 2015 May 8. pii: S0302-2838(15)00375-9. doi: 10.1016/j.eururo.2015.04.033. [Epub ahead of print]
Abstract | Similar articles






Grading
Montironi R, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Santoni M, Briganti A, Montorsi F, Cheng L.
Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?
Diagn Pathol. 2014 Oct 18;9:190. doi: 10.1186/s13000-014-0190-z.
Abstract | Full text | Similar articles






Staging





Etiology and pathogenesis

Ruppender N, Larson S, Lakely B, Kollath L, Brown L, Coleman I, Coleman R, Nguyen H, Nelson PS, Corey E, Snyder LA, Vessella RL, Morrissey C, Lam HM.
Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.
PLoS One. 2015 Jun 19;10(6):e0130565. doi: 10.1371/journal.pone.0130565. eCollection 2015.
Abstract | Full text | Similar articles

Zalucha JL, Jung Y, Joseph J, Wang J, Berry JE, Shiozawa Y, Taichman RS.
The Role of Osteoclasts in Early Dissemination of Prostate Cancer Tumor Cells.
J Cancer Stem Cell Res. 2015;3. pii: e1005.
Abstract | Full text | Similar articles






Integrative medicine

Soares ND, Teodoro AJ, Lotsch PF, Granjeiro JM, Borojevic R.
Anticancer properties of carotenoids in prostate cancer: A review.
Histol Histopathol. 2015 Jun 10:11635. [Epub ahead of print] Review.
Abstract | Full text | Similar articles

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A.
Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial.
Prostate. 2015 Jun 12. doi: 10.1002/pros.23020. [Epub ahead of print]
Abstract | Similar articles






Overall management

Climent MÁ, León-Mateos L, González Del Alba A, Pérez-Valderrama B, Méndez-Vidal MJ, Mellado B, Arranz JÁ, Sánchez-Hernández A, Cassinello J, Olmos D, Carles J.
Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Crit Rev Oncol Hematol. 2015 Jun 8. pii: S1040-8428(15)00117-1. doi: 10.1016/j.critrevonc.2015.05.019. [Epub ahead of print]
Abstract | Full text | Similar articles

Climent MA, Piulats JM, Sánchez-Hernández A, Arranz JÁ, Cassinello J, García-Donas J, González del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B; Spanish Oncology Genitourinary Group.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Crit Rev Oncol Hematol. 2012 Sep;83(3):341-52. doi: 10.1016/j.critrevonc.2012.01.002. Epub 2012 Jan 29.
Abstract | Full text | Similar articles

Saad F, Chi KN, Finelli A, Hotte SJ, Izawa J, Kapoor A, Kassouf W, Loblaw A, North S, Rendon R, So A, Usmani N, Vigneault E, Fleshner NE.
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6. doi: 10.5489/cuaj.2526.
Abstract | Full text | Similar articles

Intermediate-risk prostate cancer
D'Amico AV.
Personalizing the management of men with intermediate-risk prostate cancer.
Eur Urol. 2013 Dec;64(6):903-4. doi: 10.1016/j.eururo.2013.03.038. Epub 2013 Mar 26.
Abstract | Full text | Similar articles

Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ
A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.
Eur Urol. 2013 Dec;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033. Epub 2013 Mar 23.
Abstract | Full text | Related citations






Prognosis and outcome

Bastian PJ.
Words of wisdom. Re: Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Eur Urol. 2010 Nov 1;58(5):796. doi: 10.1016/j.eururo.2010.08.022.
Abstract | Full text | Similar articles

Bolla M.
Adjuvant or immediate external irradiation after radical prostatectomy with pelvic lymph node dissection for high-risk prostate cancer: a multidisciplinary decision.
Eur Urol. 2013 Jun;63(6):1009-10; discussion 1011-2. doi: 10.1016/j.eururo.2012.12.018. Epub 2012 Dec 17.
Abstract | Full text | Similar articles

Ho Won Kang, Hae Do Jung, Joo Yong Lee, Jong Kyou Kwon, Seong Uk Jeh, Kang Su Cho, Won Sik Ham, Young Deuk Choi
Prostate-specific antigen density predicts favorable pathology and biochemical recurrence in patients with intermediate-risk prostate cancer
Asian J Androl. 2015 Jul 7. DOI: 10.4103/1008-682X.154313. [Epub ahead of print]
Abstract | Full text

Kitagawa Y, Ueno S, Izumi K, Kadono Y, Mizokami A, Hinotsu S, Akaza H, Namiki M.
Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
World J Urol. 2015 Jun 19. [Epub ahead of print]
Abstract | Similar articles

Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y.
Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Int J Clin Oncol. 2015 Feb;20(1):176-81. doi: 10.1007/s10147-014-0696-0. Epub 2014 Apr 29.
Abstract | Similar articles

Krauss DJ, Hu C, Bahary JP, Souhami L, Gore EM, Chafe SM, Leibenhaut MH, Narayan S, Torres-Roca J, Michalski J, Zeitzer KL, Donavanik V, Sandler H, McGowan DG, Jones CU, Shipley WU.
Importance of Local Control in Early-Stage Prostate Cancer: Outcomes of Patients With Positive Post-Radiation Therapy Biopsy Results Treated in RTOG 9408.
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):863-73. doi: 10.1016/j.ijrobp.2015.03.017. Epub 2015 Mar 25.
Abstract | Similar articles

Richards K, Eggener S.
Words of wisdom: Re: Do adenocarcinomas of the prostate with Gleason Score (GS) ≤ 6 have the potential to metastasize to lymph nodes?
Eur Urol. 2013 May 1;63(5):960. doi: 10.1016/j.eururo.2013.02.014.
Abstract | Full text | Similar articles

Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI.
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?
Am J Surg Pathol. 2012 Sep;36(9):1346-52. doi: 10.1097/PAS.0b013e3182556dcd.
Abstract | Full text | Similar articles

Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, Feng Z, Carter HB, Walsh PC.
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
J Clin Oncol. 2010 Jun 10;28(17):2810-6. doi: 10.1200/JCO.2009.25.7311. Epub 2010 May 3.
Abstract | Full text | Similar articles

Thalmann GN.
Words of wisdom. Re: Do adenocarcinomas of the prostate with Gleason Score (GS) ≤ 6 have the potential to metastasize to lymph nodes?
Eur Urol. 2013 Dec 1;64(6):1013. doi: 10.1016/j.eururo.2013.09.029.
Abstract | Full text | Similar articles

Yao A, Sejima T, Iwamoto H, Masago T, Morizane S, Honda M, Takenaka A.
High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
Int J Urol. 2015 Jun 18. doi: 10.1111/iju.12839. [Epub ahead of print]
Abstract | Similar articles

Survival for nonmetastatic prostate cancer
Nguyen-Nielsen M, Liede A, Maegbaek ML, Borre M, Harving N, Hernandez RK, Sřrensen HT, Ehrenstein V.
Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy.
Cancer Epidemiol. 2015 Jun 19. pii: S1877-7821(15)00126-5. doi: 10.1016/j.canep.2015.05.008. [Epub ahead of print]
Abstract | Similar articles

Survival for castration-resistant prostate cancer
Afshar M, Evison F, James ND, Patel P.
Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.
Urol Oncol. 2015 Jun 6. pii: S1078-1439(15)00226-4. doi: 10.1016/j.urolonc.2015.05.003. [Epub ahead of print]
Abstract | Similar articles






Quality of life

Cameron MG, Kersten C, Vistad I, van Helvoirt R, Weyde K, Undseth C, Mjaaland I, Skovlund E, Fossĺ SD, Guren MG.
Palliative pelvic radiotherapy for symptomatic incurable prostate cancer - A prospective multicenter study.
Radiother Oncol. 2015 Jun 16. pii: S0167-8140(15)00286-8. doi: 10.1016/j.radonc.2015.05.021. [Epub ahead of print]
Abstract | Full text | Similar articles






Treatment

Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, Gärtner F, Rogenhofer S, Schäfers M, Essler M.
Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.
EJNMMI Res. 2015 Dec;5(1):114. doi: 10.1186/s13550-015-0114-2. Epub 2015 Jun 20.
Abstract | Full text | Similar articles

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.
Abstract | Full text | Comments | Similar articles

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN.
A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29.
Abstract | Full text | Similar articles

Barkin J.
Risks, benefits, and approaches to hormonal blockade in prostate cancer. Highlights from the European Association of Urology Meeting, March 20-24, 2015, Madrid, Spain.
Can J Urol. 2015 Jun;22(3):7847-52.
Abstract | Full text | Similar articles

Body JJ, Casimiro S, Costa L.
Targeting bone metastases in prostate cancer: improving clinical outcome.
Nat Rev Urol. 2015 Jun;12(6):340-56. doi: 10.1038/nrurol.2015.90. Epub 2015 May 5.
Abstract | Similar articles

Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.
Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
Eur Urol. 2015 Aug;68(2):317-24. doi: 10.1016/j.eururo.2014.07.028. Epub 2014 Aug 6.
Abstract | Full text | Similar articles

Brodszky V, Péntek M, Baji P, Rencz F, Géczi L, Szűcs M, Berczi C, Gulácsi L.
[Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].
Magy Onkol. 2014 Sep;58(3):189-97. Epub 2014 Aug 2. Review. Hungarian.
Abstract | Full text | Similar articles

Elena Castro,1,2 Nuria Romero,1,2 David Olmos1,2
State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer
EMJ Oncology, November 17, 2014
Abstract | Full text

Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F.
Treatment of mCRPC in the AR axis-targeted therapy resistant state.
Ann Oncol. 2015 Jun 22. pii: mdv267. [Epub ahead of print]
Abstract | Full text | Similar articles

Dorff TB, Pal SK.
Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases.
Oncology (Williston Park). 2015 Jun 15;29(6):424, 426.
Abstract | Full text | Similar articles

Hannah C.P. Wilson, S. Imran A. Shah, Patricia Price, Paul D. Abel
Re: State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer – Forward to the past – Again
EMJ Oncology, May 7, 2015
Abstract | Full text

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.
Abstract | Similar articles

Francini E, Roviello G.
How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue.
Tumour Biol. 2014 Aug;35(8):7391-2. doi: 10.1007/s13277-014-2145-0. Epub 2014 May 30.
Abstract | Similar articles

Glodé LM.
Progress in Prostate Cancer (at Last!).
Oncology (Williston Park). 2015 Jun;29(6):407, 414.
Abstract | Full text | Similar articles

Graff JN, Beer TM.
Reducing Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer.
Oncology (Williston Park). 2015 Jun 15;29(6):416-23.
Abstract | Full text | Similar articles

Greasley R, Khabazhaitajer M, Rosario DJ.
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.
Cancer Manag Res. 2015 Jun 12;7:153-64. doi: 10.2147/CMAR.S50585. eCollection 2015.
Abstract | Full text | Similar articles

Jones RJ.
Sequencing Systemic Therapies in Advanced Prostate Cancer: Spoiled for Choice But Not for Evidence.
Eur Urol. 2014 Jan 2. pii: S0302-2838(13)01463-2. doi: 10.1016/j.eururo.2013.12.053. [Epub ahead of print]
Abstract | Full text | Related citations


Heemers HV, Mohler JL.
Words of wisdom. Re: Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Eur Urol. 2014 Sep;66(3):597. doi: 10.1016/j.eururo.2014.06.032.
Abstract | Full text | Similar articles

Heidenreich A, Porres D.
Prostate cancer: treatment sequencing for CRPC--what do we know?
Nat Rev Urol. 2014 Apr;11(4):189-90. doi: 10.1038/nrurol.2014.36. Epub 2014 Mar 4.
Abstract | Similar articles

Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS.
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
Eur J Cancer. 2015 Jun 13. pii: S0959-8049(15)00450-5. doi: 10.1016/j.ejca.2015.05.019. [Epub ahead of print]
Abstract | Full text | Similar articles

Hutson PR.
Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer.
Clin Pharmacokinet. 2015 Jun 16. [Epub ahead of print]
Abstract | Full text | Similar articles

Lei JH, Liu LR, Wei Q, Song TR, Yang L, Meng Y, Han P.
Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis.
Asian J Androl. 2015 Apr 7. doi: 10.4103/1008-682X.150840. [Epub ahead of print]
Abstract | Full text | Similar articles

Lien LM, Tvedt B, Heinrich D.
Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride.
Int J Urol Nurs. 2015 Mar;9(1):3-13.
Abstract | Full text | Similar articles

Loriot Y, Fizazi K.
Towards random sequencing or precision medicine in castration-resistant prostate cancer?
Eur Urol. 2014 Jan;65(1):37-8. doi: 10.1016/j.eururo.2013.09.019. Epub 2013 Sep 19.
Abstract | Full text | Similar articles

Markowski MC, Pienta KJ.
Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer.
Asian J Androl. 2015 Apr 10. doi: 10.4103/1008-682X.150843. [Epub ahead of print]
Abstract | Full text | Similar articles

Matsubara N, Uemura H, Satoh T, Suzuki H, Nishiyama T, Uemura H, Hashine K, Imanaka K, Ozono S, Akaza H.
A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study).
Jpn J Clin Oncol. 2014 Dec;44(12):1216-26. doi: 10.1093/jjco/hyu149. Epub 2014 Oct 15.
Abstract | Full text | Similar articles

McNeel DG, Chen YH, Gulley JL, Dwyer AJ, Madan RA, Carducci MA, DiPaola RS.
Randomized Phase II Trial of Docetaxel with or without PSA-TRICOM Vaccine in Patients with Castrate-Resistant Metastatic Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E1809).
Hum Vaccin Immunother. 2015 Jun 25:0. [Epub ahead of print]
Abstract | Similar articles

Moul JW.
Hormone naďve prostate cancer: predicting and maximizing response intervals.
Asian J Androl. 2015 Jun 26. doi: 10.4103/1008-682X.152821. [Epub ahead of print]
Abstract | Full text | Similar articles

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.
Clinical activity of enzalutamide in Docetaxel-naďve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
Prostate. 2014 Nov;74(15):1560-8. doi: 10.1002/pros.22874. Epub 2014 Aug 31.
Abstract | Similar articles

Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S.
Enzalutamide After Docetaxel and Abiraterone Acetate Treatment in Prostate Cancer: A Pooled Analysis of 10 Case Series.
Clin Genitourin Cancer. 2015 Jun;13(3):193-198. doi: 10.1016/j.clgc.2014.10.006. Epub 2014 Nov 7.
Abstract | Similar articles

Petrioli R, Francini E, Laera L, Fiaschi AI, Ponchietti R, Roviello G.
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
Cancer Chemother Pharmacol. 2015 Jun 17. [Epub ahead of print]
Abstract | Similar articles

Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.
Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents.
Eur Urol. 2013 Dec 17. pii: S0302-2838(13)01308-0. doi: 10.1016/j.eururo.2013.11.044. [Epub ahead of print]
Abstract | Full text | Related citations

Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, Vrabcova P, Kubackova K, Gasova Z, Jarolim L, Babjuk M, Spisek R, Bartunkova J, Fucikova J.
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Oncotarget. 2015 May 29. [Epub ahead of print]
Abstract | Similar articles

Rajan P, Frew JA, Wilson JM, Azzabi AS, McMenemin RM, Stockley J, Soomro NA, Durkan G, Pedley ID, Leung HY.
Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
Urol Oncol. 2015 Jun 16. pii: S1078-1439(15)00235-5. doi: 10.1016/j.urolonc.2015.05.012. [Epub ahead of print]
Abstract | Similar articles

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F.
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
Eur Urol. 2014 Nov;66(5):815-25. doi: 10.1016/j.eururo.2014.02.056. Epub 2014 Mar 6.
Abstract | Full text | Similar articles

Renzulli JF 2nd, Collins J, Mega A.
Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer.
J Multidiscip Healthc. 2015 Jun 5;8:279-86. doi: 10.2147/JMDH.S81007. eCollection 2015.
Abstract | Full text | Similar articles

Schally AV, Block NL, Rick FG.
New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.
Asian J Androl. 2015 Jun 26. doi: 10.4103/1008-682X.152819. [Epub ahead of print]
Abstract | Full text | Similar articles

Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV.
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
Eur Urol. 2014 Jan;65(1):30-6. doi: 10.1016/j.eururo.2013.06.042. Epub 2013 Jul 2.
Abstract | Full text | Similar articles

Stein CA.
Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.
Clin Genitourin Cancer. 2015 Jun 6. pii: S1558-7673(15)00119-6. doi: 10.1016/j.clgc.2015.05.005. [Epub ahead of print]
Abstract | Similar articles

Suzman D, Eisenberger M.
Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. Epub 2014 Apr 13.
Abstract | Full text | Similar articles

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844. Epub 2014 Jul 22.
Abstract | Similar articles

Thomsen FB, Rřder MA, Rathenborg P, Brasso K, Borre M, Iversen P.
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
Scand J Urol. 2014 Jun;48(3):268-75. doi: 10.3109/21681805.2013.860189. Epub 2013 Nov 21.
Abstract | Full text | Similar articles

Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.
A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Jpn J Clin Oncol. 2015 May 15. pii: hyv070. [Epub ahead of print]
Abstract | Similar articles

Yamada Y, Okihara K, Iwata T, Masui K, Kamoi K, Yamada K, Miki T.
Salvage brachytherapy for locally recurrent prostate cancer after external beam radiotherapy.
Asian J Androl. 2015 Jun 23. doi: 10.4103/1008-682X.151391. [Epub ahead of print]
Abstract | Full text | Similar articles

Zhou ZR, Liu SX, Zhang TS, Xia J, Li B.
Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Asian Pac J Cancer Prev. 2014;15(3):1313-20.
Abstract | Full text | Similar articles

Reversing docetaxel resistance
Zhu Y, Liu C, Armstrong C, Lou W, Sandher A, Gao AC.
Anti-androgens inhibit ABCB1 efflux and ATPase activity and reverse docetaxel resistance in advanced prostate cancer.
Clin Cancer Res. 2015 May 20. pii: clincanres.0269.2015. [Epub ahead of print]
Abstract | Similar articles

Sequencing of agents for castration-resistant prostate cancer.
Hurwitz M, Petrylak DP.
Sequencing of agents for castration-resistant prostate cancer.
Oncology (Williston Park). 2013 Nov;27(11):1144-9, 1154-8.
Abstract | Full text | Similar articles

Kessler ER, Flaig TW.
Sequencing medical therapy in prostate cancer: not as easy as 1-2-3.
Oncology (Williston Park). 2013 Nov;27(11):1158-60.
Abstract | Full text | Similar articles

Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G.
Sequencing of agents in castration-resistant prostate cancer.
Lancet Oncol. 2015 Jun;16(6):e279-e292. doi: 10.1016/S1470-2045(15)70033-1. Epub 2015 May 27.
Abstract | Similar articles

Shore ND.
The success of therapies for metastatic CRPC continues.
Oncology (Williston Park). 2013 Nov;27(11):1160-1.
Abstract | Full text | Similar articles

Stereotactic radiotherapy for recurrence in the prostatic bed
Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, Bonucci I, Franceschini D, Di Brina L, Baki M, Simontacchi G, Meattini I, Carini M, Serni S, Nicita G, Livi L.
CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed.
World J Urol. 2015 Jun 11. [Epub ahead of print]
Abstract | Similar articles

Fuller DB, Wurzer J, Shirazi R, Bridge SS, Law J, Mardirossian G.
High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Pract Radiat Oncol. 2015 Jun 6. pii: S1879-8500(15)00157-5. doi: 10.1016/j.prro.2015.04.009. [Epub ahead of print]
Abstract | Similar articles

Treatment complications
Balducci L, Pow-Sang JM.
Colorectal Cancer: The Last Nail in the Coffin for Androgen Deprivation Therapy for Prostate Cancer?
Cancer Control. 2015 Apr;22(2):259-60.
Abstract | Full text | Similar articles

Lu Y, Ljung R, Martling A, Lindblad M.
Risk of Colorectal Cancer by Subsite in a Swedish Prostate Cancer Cohort.
Cancer Control. 2015 Apr;22(2):263-70.
Abstract | Full text | Similar articles

Martling A.
Does Androgen Deprivation Therapy for Prostate Cancer Increase the Risk of Colorectal Cancer?
Cancer Control. 2015 Apr;22(2):261-2.
Abstract | Full text | Similar articles

Reyes C, Hitz M, Prieto-Alhambra D, Abrahamsen B.
Risks and Benefits of Bisphosphonate Therapies.
J Cell Biochem. 2015 Jun 20. doi: 10.1002/jcb.25266. [Epub ahead of print]
Abstract | Full text | Similar articles

Schmid M, Sammon JD, Reznor G, Kapoor V, Speed JM, Abdollah FA, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Sun M, Trinh QD.
The dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
BJU Int. 2015 Jun 13. doi: 10.1111/bju.13203. [Epub ahead of print]
Abstract | Similar articles






 

This website is certified by Health On the Net Foundation. Click to verify. www.prostate-cancer-today.org
Home Prostate OncologyRecurrent Prostate Cancer
LibraryPublications
About UsE-mail Alert ServiceJournals Privacy Policy